Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cellular Gatekeepers Do More than Open Doors for Drugs, UCSF Study Finds

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Discovery could change the way we design medications and shed light on side effects.

The cellular gatekeepers that escort the most common pharmaceuticals into our cells continue to work within the cells as well, according to a UC San Francisco discovery that could transform drug design and lead to new ways to treat disease.

Almost half of approved pharmaceuticals — for cancer, heart failure, inflammatory diseases, and others — act through gatekeepers on cell surfaces known as G-protein-coupled receptors (GPCRs). More than 1,000 specific GPCR proteins play roles in nerve signaling, immune responses, sensory perception and many other physiological phenomena governed by the trillions of cells within our bodies.

A team led by UCSF cell biologist Mark von Zastrow, MD, PhD, now has demonstrated that these receptor proteins can remain active longer than expected — even after being pulled into the cell after the attachment of a drug or natural activator. The researchers also demonstrated the value of a new way to study the receptors once they’re inside the cell, one which may shed light on why therapeutics have unexpected effects or varying degrees of effectiveness, according to von Zastrow. The study appeared in the March 28 issue of Nature.

“From the standpoint of drug development, this may open a vast new range of targets, involving the cellular machinery that determines whether or not these key receptor molecules are present on the cell surface,” said von Zastrow, a cell biologist who holds the Friends of LPPI Endowed Chair for Research in Schizophrenia and Depression at UCSF.

Using small, genetically engineered “nanobodies” — tiny antibodies similar to those naturally present in camels, but in few other animals — the researchers were able to trace short-lived chemical liaisons between molecules and to demonstrate that a GPCR known as the beta-adrenergic receptor remains active for minutes after it is internalized within the cell. The same receptor often has served as a model for studies of GPCRs, including studies by Brian K. Kobilka, MD, of Stanford University and Robert J. Lefkowitz, MD, of Duke University, who shared the 2012 Nobel Prize in Chemistry for discoveries related to GPCRs.

Many drugs mimic the shapes of natural signaling molecules and block or activate specific GPCRs. When activated, the receptor acts upon another protein — its own specific partner within a class of enzymes known as G proteins. In a chain reaction, G proteins then initiate their own effects downstream in the cell’s biochemical pathways.

The small size and flexibility of the engineered nanobodies allow them to attach to parts of proteins that other antibodies can’t reach. Von Zastrow’s team developed one fluorescent nanobody to bind selectively to the transitional, activated form of the beta adrenergic receptor, and another to bind to the activated form of its G protein. This enabled the researchers to trace the receptors’ activity as they moved inside the cell from the cell surface.

Noting that different drugs can have different effects, even when targeting the same receptor, von Zastrow suggests that nanobodies might help drug developers gain insight into whether these differences are caused by attachments to different transient shapes formed by GPCRs. The engineered nanobodies could serve as tools to tag key activated forms of GPCRs as the receptors interact with other molecules. Nanobodies might even be adaptable for high-throughput drug screening, von Zastrow suggested.

Tracking GPCRs in the Cell

UCSF postdoctoral fellow Roshanak Irannejad, PhD, who performed most of the key experiments and was first author on the paper, used isoproterenol — a drug for treating slow heart beat — to activate the beta-adrenergic receptor and trace activity over time and space, on and within the cells of a human kidney cell line.

Von Zastrow is an expert on endosomes, small membranous sacs pinched off from cell membranes and taken into cells. Each cell may contain 1,000 or more endosomes. Different endosomes contain different molecules. GPCRs were thought to be inactive within endosomes, where they awaited one of two fates — being sent to the cell’s trash heap, or being recycled to the cell surface. Once activated, GPCRs are taken into the cell via endosomes.

“It was previously thought that once the receptor is taken away from the cell’s surface that it no longer does anything until it is recycled back to the surface later,” he said. “Our data clearly show that’s not true — the internalized receptors actually are active and doing specific things within cells.”

Von Zastrow speculates that endosomes might sometimes help redeploy GPCRs to different parts of the cell surface where they are needed, a function that might prove especially valuable to oddly shaped cells such as neurons, which have long, branching processes — axons and dendrites — and large surface areas. Drugs might one day be targeted to manipulate the internalization and movement of specific GPCRs via endosomes, von Zastrow said.

Other UCSF authors of the Nature report include assistant professors Bo Huang, PhD, and Hana El-Samad, PhD; and postdoctoral fellows Jin Tomshine PhD, Jonathan Tomshine PhD, and Michael Chevalier PhD. Collaborators from the University of Michigan, the University of Copenhagen and Vrije Universiteit Brussel, in Belgium, participated in the study.

The research was funded by the National Institutes of Health and the American Heart Association.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rare Childhood Leukemia Reveals Surprising Genetic Secrets
A coalition of leukemia researchers led by scientists from UC San Francisco has discovered surprising genetic diversity in juvenile myelomonocytic leukemia (JMML), a rare but aggressive childhood blood cancer.
Thursday, October 15, 2015
Simple Technology Makes CRISPR Gene Editing Cheaper
University of California, Berkeley, researchers have discovered a much cheaper and easier way to target a hot new gene editing tool, CRISPR-Cas9, to cut or label DNA.
Friday, July 24, 2015
Delivering Drugs to the Right Place
Thomas Weimbs has developed a targeted drug delivery method that could potentially slow the progression of polycystic kidney disease.
Monday, June 29, 2015
Designing New Pain Relief Drugs
Researchers have identified the molecular interactions that allow capsaicin to activate the body’s primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain.
Thursday, June 11, 2015
Engineers Crack DNA Code of Autoimmune Disorders
Researchers have identified an unexpectedly general set of rules that determine which molecules can cause the immune system to become vulnerable to the autoimmune disorders lupus and psoriasis.
Wednesday, June 10, 2015
Genetic Markers for Detecting and Treating Ovarian Cancer
Custom bioinformatics algorithm identifies human mRNAs that distinguish ovarian cancer cells from normal cells and provide new therapeutic targets
Wednesday, May 27, 2015
Industry-Sponsored Academic Inventions Spur Increased Innovation
Analysis questions assumption that corporate support skews science toward inventions that are less useful than those funded by the government or non-profit organizations.
Monday, March 24, 2014
Chemical Signature for Fast Form of Parkinson's Found
The physical decline experienced by Parkinson's disease patients eventually leads to disability and a lower quality of life.
Monday, November 25, 2013
Digging Deeper Into Cancer
What a pathologist looks for in a Pap test sample, but hopes not to find, are oddly shaped cells with abnormally large nuclei. The same is true for prostate and lung cancer biopsies.
Tuesday, November 19, 2013
Discovery Could Lead to Saliva Test for Pancreatic Cancer
The disease is typically diagnosed through an invasive and complicated biopsy.
Tuesday, October 15, 2013
Biologists Find New Method for Discovering Antibiotics
Biologists have developed a revolutionary new method for identifying and characterizing antibiotics.
Tuesday, September 17, 2013
Potential Drug Discovered for Severe Form of Epilepsy
UCSF study found effectiveness of antihistamine on zebrafish bred to mimic disease.
Thursday, September 05, 2013
Potential New Drug for Inflammatory Bowel Disease
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis.
Monday, September 02, 2013
Dentistry School Receives $5M to Study Saliva Biomarkers
Imagine having a sample of your saliva taken at the dentist's office, and then learning within minutes whether your risk for stomach cancer is higher than normal.
Thursday, August 15, 2013
Brain Anomolies are Potential Biomarkers for Autism
Brain anomalies may serve as potential biomarkers for the early identification of the neurodevelopmental disorder.
Wednesday, July 10, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos